Oncternal sells assets for up to $68m and calls it...
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based Ho’ola Therapeutics has acquired Oncternal’s zilovertamab and ONCT-808, two candidates...
